CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7294 result(s)

Inteferon-based therapies for chronic Hepatitis C virus infection: an assessment of clinical outcomes

Last Updated: May 13, 2004
Result type: Reports

Technology Name Interferon (IFN)-based antiviral therapies: standard IFN plus ribavirin versus standard IFN therapy alone standard IFN plus ribavirin versus pegylated IFN plus ribavirin Disease/Condition Chronic hepatitis C virus (HCV) infection Technology Description IFNs are human proteins that inhibit virus replication in infected c...

Economic evaluation of Glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention with stenting

Last Updated: March 11, 2005
Result type: Reports

Technology Name Glycoprotein IIb/IIIa inhibitor drugs (abciximab and eptifibatide) Disease or Condition Blood clots (thrombi) and atherosclerotic plaque can block the coronary artery supplying blood to the heart. Blockage may result in heart pain (angina) or acute coronary syndrome, including unstable angina and myocardial infarction. Percuta...

CT and MRI for Selected Clinical Disorders: a Systematic Review of Clinical Systematic Reviews

Last Updated: October 21, 2005
Result type: Reports

Technology Computed Tomography (CT) and Magnetic Resonance Imaging (MRI). Disease This report explores 13 conditions for which the use of CT and MRI remain controversial: arteriovenous malformations carotid artery disease, cerebral aneurysms, coronary artery disease, headaches, head injuries, lung cancer screening, peripheral vascular disease...

Portable Ultrasound Devices in Emergency Departments

Last Updated: March 10, 2006
Result type: Reports

Context and Policy Issues In the emergency department (ED), prompt and accurate diagnoses made by physicians are a prerequisite for the effective and timely treatment of patients with serious illnesses and injuries. Modern diagnostic methods such as ultrasonography (U/S) and computed tomographic (CT) scanning play a role in enhancing the qualit...

Saxagliptin + metformin (Komboglyze)

Last Updated: June 6, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Saxagliptin + metformin
Indications: Diabetes Mellitus, Type 2

  • Brand Name: Komboglyze
  • Manufacturer: Bristol-Myers Squibb / AstraZeneca Canada Inc.
  • Project Number: SR0336-000
  • Project Status: Withdrawn
  • Submission Type: Initial

Rotigotine (Neupro)

Last Updated: July 31, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Rotigotine
Indications: Parkinson’s Disease

  • Brand Name: Neupro
  • Manufacturer: UCB Canada Inc.
  • Project Number: SR0344-000
  • Project Status: Complete
  • Submission Type: Initial

Riociguat (Adempas)

Last Updated: September 30, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Riociguat
Indications: Pulmonary hypertension, chronic thromboembolic

  • Brand Name: Adempas
  • Manufacturer: Bayer Inc.
  • Project Number: SR0353-000
  • Project Status: Complete
  • Submission Type: Initial

Sofosbuvir (Sovaldi)

Last Updated: October 1, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Sofosbuvir
Indications: Hepatitis C, chronic

  • Brand Name: Sovaldi
  • Manufacturer: Gilead Sciences Canada Inc.
  • Project Number: SR0356-000
  • Project Status: Complete
  • Submission Type: Initial

Mirabegron (Myrbetriq)

Last Updated: November 27, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Mirabegron
Indications: Bladder, overactive

  • Brand Name: Myrbetriq
  • Manufacturer: Astellas Pharma Canada Inc.
  • Project Number: SR0363-000
  • Project Status: Complete
  • Submission Type: Initial

Macitentan (Opsumit)

Last Updated: December 16, 2013
Result type: Reports
Product Line: Reimbursement Review
Generic Name: Macitentan
Indications: Pulmonary arterial hypertension

  • Brand Name: Opsumit
  • Manufacturer: Actelion Pharmaceuticals Canada Inc.
  • Project Number: SR0364-000
  • Project Status: Complete
  • Submission Type: Initial